CD4 and neoplasm: In vitro, the KSP inhibitor was shown to promote immunogenic cell death, while in vivo, TWEAKR-ADC showed no antitumor activity in immunocompromised mice but in immunocompetent ones it reduced tumor growth and increased the presence of CD45+ leukocytes and CD4+ and CD8+ T lymphocytes in tumor samples demonstrating it induces an anticancer immune response [223].